Pharmacogenomics for the primary care provider: Why should we care?

Cleveland Clinic Journal of Medicine

Volumn 78, Issue 4, 2011, Pages 241-242

  Teng, Kathryn ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EDITORIAL; GENERAL PRACTITIONER; HUMAN; METHODOLOGY; PERSONALIZED MEDICINE; PHARMACOGENETICS;

HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS; PHYSICIANS, PRIMARY CARE;

EID: 79954498316     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.78a.11017     Document Type: Editorial

References (5)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279:1200-1205.
2. Field TS, Gilman BH, Subramanian S, Fuller JC, Bates DW, Gurwitz JH. The costs associated with adverse drug events among older adults in the ambulatory setting. Med Care 2005; 43:1171-1176.
3. Kitzmiller JP, Groen DK, Phelps MA, Sadee W. Pharmacogenomic testing: relevance in medical practice. Why drugs work in some patients but not others. Cleve Clin J Med 2011; 78:243-257.
4. Thuerauf N, Lunkenheimer J. The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants. Eur Arch Psychiatry Clin Neurosci 2006; 256:287-293.
5. Schwarz EB, McNamara M, Miller RG, Walsh JM. Update in women's health for the general internist. J Gen Intern Med 201; 26:207-213.